Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19859668 | 1.00 | ADORA2A (0.39) | ADORA2AADORA2BADORA1ADORA3PRKAG1 | |
| SCHEMBL19859744 | 0.89 | ADORA3 (0.42) | ADORA2AADORA2BADORA1ADORA3PRKAG1 | |
| SCHEMBL19859767 | 0.89 | NT5E (0.35) | ADORA2AADORA2BADORA1ADORA3TYMP | |
| SCHEMBL19859685 | 0.88 | PRMT5 (0.35) | — | |
| SCHEMBL19859340 | 0.87 | ADORA2A (0.40) | ADORA2AADORA2BADORA1ADORA3PRKAG1 | |
| SCHEMBL21046398 | 0.86 | PRMT5 (0.36) | — | |
| SCHEMBL19859871 | 0.86 | PRMT5 (0.36) | — | |
| SCHEMBL19859365 | 0.84 | ADORA3 (0.51) | ADORA2AADORA2BADORA1ADORA3PRKAG1 | |
| SCHEMBL15833128 | 0.84 | TYMP (0.38) | TYMP | |
| SCHEMBL19859680 | 0.83 | ADORA3 (0.43) | ADORA2AADORA2BADORA1ADORA3PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916217-A | Alkynyl nucleoside analogs for the treatment of hepatitis E | 杨森制药公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4138850-A1 | ALKYNYL NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | Janssen Pharmaceuticals, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021209425-A9 | ALKYNYL NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | Janssen Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |